Prospective Follow-Up of Novel Markers of Bone Turnover in Persistent Asthmatics Exposed to Low and High Doses of Inhaled Ciclesonide over 12 Months

Keyphrases

• Adrenal Suppression 40%
• Airway Control 20%
• Airway Hyperresponsiveness 80%
• Amino 40%
• Asthma Symptoms 40%
• Asthmatic 100%
• Bone Metabolism 20%
• Bone Turnover 40%
• Bone Turnover Markers 100%
• Bronchial Challenge 40%
• C-telopeptide 20%
• Carboxyl Terminus 20%
• Ciclesonide 100%
• Creatinine Ratio 40%
• Cross-linked 20%
• Group-based 20%
• High Dose 100%
• Inhaled Corticosteroid Therapy 20%
• Mannitol 40%
• No Significant Difference 20%
• Parallel Trials 20%
• Persistent Asthma 20%
• PIIINP 60%
• Primary Care 20%
• Propeptide 40%
• Prospective Follow-up 100%
• Prospective Randomized Trial 20%
• Pulmonary Function 20%
• Reliever Use 20%
• Resorption 20%
• Scotland 20%
• Sensitive Biomarker 20%
• Stored Samples 20%
• Systemic Side Effects 40%
• Tayside 20%
• Telopeptide 20%
• Type I Collagen 60%
• Type III Collagen 20%
• Urinary Cortisol 40%
• Use Function 20%

Medicine and Dentistry

• Adrenal Suppression 40%
• Adverse Effect 20%
• Adverse Event 20%
• Airway Management 20%
• Amino Terminal Sequence 40%
• Asthma 60%
• Biological Marker 20%
• Bone Remodeling 20%
• Bone Turnover 100%
• Ciclesonide 100%
• Collagen Type 1 60%
• Collagen Type 3 20%
• Corticosteroid Therapy 20%
• Creatinine 40%
• Drug Megadose 100%
• Group Trial 20%
• Hydrocortisone 40%
• Low Drug Dose 100%
• Lung Function 20%
• Mannitol 40%
• Ossification 20%
• Post-Hoc Analysis 20%
• Primary Health Care 20%
• Respiratory Tract Allergy 80%
• Salicylate Sodium 20%
• Telopeptide 40%
• Urinary System 40%

Pharmacology, Toxicology and Pharmaceutical Science

• Adverse Event 20%
• Asthma 60%
• Biological Marker 20%
• Ciclesonide 100%
• Collagen Type 1 60%
• Collagen Type 3 20%
• Creatinine 40%
• Group Trial 20%
• Hydrocortisone 40%
• Mannitol 40%
• Respiratory Tract Allergy 80%
• Salicylate Sodium 20%
• Telopeptide 40%